Jpmorgan Chase & CO Intellia Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 649,054 shares of NTLA stock, worth $9.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

649,054

Previous 669,105 3.0%

Holding current value

$9.28 Million

Previous $15 Million 10.93%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$19.72 - $27.36 $395,405 - $548,595	-20,051 Reduced 3.0%	649,054 $13.3 Million
Q2 2024 Aug 12, 2024	BUY	$20.02 - $27.22 $2.52 Million - $3.43 Million	125,998 Added 23.2%	669,105 $15 Million
Q1 2024 May 10, 2024	SELL	$23.82 - $32.8 $2.22 Million - $3.05 Million	-93,010 Reduced 14.62%	543,107 $14.9 Million
Q4 2023 Feb 12, 2024	BUY	$23.16 - $32.34 $488,699 - $682,406	21,101 Added 3.43%	636,117 $19.4 Million
Q3 2023 Nov 14, 2023	SELL	$31.62 - $45.78 $1.21 Million - $1.75 Million	-38,334 Reduced 5.87%	615,016 $19.4 Million
Q2 2023 Aug 11, 2023	SELL	$34.58 - $46.03 $614,901 - $818,505	-17,782 Reduced 2.65%	653,350 $26.6 Million
Q1 2023 May 18, 2023	BUY	$33.3 - $44.82 $3.66 Million - $4.93 Million	109,960 Added 19.59%	671,132 $25 Million
Q1 2023 May 11, 2023	SELL	$33.3 - $44.82 $3.38 Million - $4.55 Million	-101,445 Reduced 15.31%	561,172 $20.9 Million
Q4 2022 Feb 13, 2023	BUY	$33.21 - $62.69 $722,981 - $1.36 Million	21,770 Added 3.4%	662,617 $23.1 Million
Q3 2022 Nov 14, 2022	SELL	$53.92 - $71.7 $87,188 - $115,938	-1,617 Reduced 0.25%	640,847 $35.9 Million
Q2 2022 Aug 11, 2022	BUY	$38.49 - $76.21 $557,912 - $1.1 Million	14,495 Added 2.31%	642,464 $33.3 Million
Q1 2022 May 11, 2022	SELL	$58.27 - $118.99 $2.35 Million - $4.81 Million	-40,398 Reduced 6.04%	627,969 $45.6 Million
Q4 2021 Feb 10, 2022	BUY	$100.76 - $138.36 $17.6 Million - $24.2 Million	174,640 Added 35.37%	668,367 $79 Million
Q3 2021 Nov 12, 2021	BUY	$132.37 - $176.78 $65.4 Million - $87.3 Million	493,727 New	493,727 $66.2 Million

Others Institutions Holding NTLA

# of Institutions

313

Shares Held

91.5M

Call Options Held

442K

Put Options Held

880K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.09B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Intellia Therapeutics, Inc. Transaction History